CRBU
Caribou Biosciences, Inc.Company Information
- Company Name
- Caribou Biosciences, Inc.
- CIK
- CIK0001619856
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- CRBU: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- CRBU
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-03-14
- Last sale
- 2026-02-25
- Shares purchased (TTM)
- 20,000
- Shares sold (TTM)
- 24,317
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 46,588,895
- Shares outstanding
- 100,985,698
- Ownership
- 46.13%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- -2.48%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 26 | 12 | 12 | 11 | 25 | 29 | 16 | 32 | 38 | 49 | 51 | 104 | ||||||
| Available For Sale Securities Debt Securities Current | 86 | 106 | 127 | 136 | 159 | 179 | 193 | 196 | 224 | 245 | 278 | 234 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | ||||||
| Contract With Customer Asset Net Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | ||||||
| Other Receivables | - | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Other Receivables Net Current | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 2 | 2 | 3 | 5 | 6 | 6 | 7 | 7 | 6 | 7 | 6 | 7 | ||||||
| Assets Current | 117 | 122 | 145 | 156 | 193 | 217 | 219 | 237 | 271 | 305 | 339 | 351 | ||||||
Assets Noncurrent | ||||||||||||||||||
| Equity Method Investments | - | - | 0 | 0 | 0 | 9 | 9 | 9 | 9 | 8 | 8 | 8 | ||||||
| Available For Sale Securities Debt Securities Noncurrent | 2 | 1 | 4 | 12 | 0 | 4 | 40 | 53 | 50 | 52 | 44 | 58 | ||||||
| Property Plant And Equipment Net | 5 | 6 | 7 | 8 | 8 | 19 | 19 | 20 | 20 | 19 | 18 | 17 | ||||||
| Operating Lease Right Of Use Asset | 17 | 17 | 18 | 16 | 16 | 20 | 20 | 20 | 21 | 22 | 22 | 23 | ||||||
| Other Assets Noncurrent | 2 | 2 | 2 | 4 | 4 | 5 | 6 | 5 | 2 | 2 | 2 | 2 | ||||||
| Assets | 143 | 149 | 175 | 195 | 221 | 274 | 313 | 344 | 373 | 407 | 432 | 458 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 3 | 4 | 6 | 4 | 3 | 4 | 2 | 3 | 3 | 6 | 3 | 2 | ||||||
| Accrued Liabilities Current | 13 | 14 | 17 | 19 | 21 | 20 | 24 | 25 | 24 | 19 | 21 | 18 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 3 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Contract With Customer Liability Current | 0 | 1 | 2 | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | ||||||
| Liabilities Current | 18 | 20 | 25 | 28 | 29 | 28 | 31 | 32 | 31 | 29 | 28 | 25 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Contract With Customer Liability Noncurrent | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 4 | 5 | 5 | 6 | 7 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | - | - | - | - | - | - | 0.00 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | - | - | - | - | - | - | 10 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Operating Lease Liability Noncurrent | 25 | 26 | 26 | 23 | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 26 | ||||||
| Deferred Income Tax Liabilities Net | - | - | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Liabilities | 45 | 47 | 53 | 53 | 55 | 56 | 60 | 63 | 62 | 64 | 64 | 59 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 744 | 724 | 719 | 712 | 709 | 705 | 701 | 693 | 689 | 684 | 668 | 664 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -646 | -622 | -597 | -570 | -542 | -488 | -448 | -413 | -378 | -341 | -299 | -265 | ||||||
| Stockholders Equity | 98 | 102 | 122 | 142 | 166 | 217 | 253 | 281 | 310 | 343 | 368 | 398 | ||||||
| Liabilities And Stockholders Equity | 143 | 149 | 175 | 195 | 221 | 274 | 313 | 344 | 373 | 407 | 432 | 458 | ||||||
| Related Party | - | - | 0 | -1 | 0 | 2 | 0 | 0 | 0 | 2 | 2 | -5 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 106 | 97 | 95 | 93 | 93 | 93 | 92 | 91 | 90 | 90 | 88 | 88 | ||||||
| Shares Outstanding | 106 | 97 | 95 | 93 | 93 | 93 | 92 | 91 | 90 | 90 | 88 | 88 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialCaribou Biosciences, Inc. (CRBU) — SEC Financial Statements & Analysis
Caribou Biosciences, Inc. (CRBU) is a biological products, (no diagnostic substances) company, incorporated in DE. Caribou Biosciences, Inc. trades on Nasdaq as: CRBU. Caribou Biosciences, Inc. (CRBU)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on that filing, Caribou Biosciences, Inc. carries a market cap of $177.73M, a P/E ratio of -1.72x, a P/B ratio of 1.81x, a P/S ratio of 17.71x, an enterprise value of $151.54M, and an EV/EBITDA multiple of -1.42x. On profitability, it posts an operating margin of -1090.90%, a net margin of -1030.42%, a Return on Equity (ROE) of -78.27%, a Return on Assets (ROA) of -56.87%, and a Return on Invested Capital (ROIC) of -102.71%. Per share, it reports EPS of $-1.02, diluted EPS of $-1.02, free cash flow per share of $-0.95, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 10.02% year-over-year, net income growth of -37.05% year-over-year, and EPS growth of -42.01% year-over-year. On the balance sheet, it maintains a current ratio of 6.49x, a quick ratio of 6.36x, working capital of $98.62M, a debt-to-equity ratio of 0.46x, a debt ratio of 0.31, free cash flow of $-96.18M (TTM), and net debt of $-26.19M. Figures sourced from SEC EDGAR.
- Market Cap
- $177.73M
- P/E TTM
- -1.72x
- EPS TTM
- $-1.02
- P/B TTM
- 1.81x
- ROE TTM
- -78.27%
- ROA TTM
- -56.87%
- Debt To Equity
- 0.46x
- Free Cash Flow TTM
- $-96.18M
- Net Revenue TTM Growth 1Y
- 10.02%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Caribou Biosciences, Inc. in?
Caribou Biosciences, Inc. (CRBU) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does CRBU trade on?
Caribou Biosciences, Inc. (CRBU) trades on the Nasdaq.
Where is Caribou Biosciences, Inc. incorporated?
Caribou Biosciences, Inc. is incorporated in DE.
When was Caribou Biosciences, Inc. (CRBU)'s most recent SEC filing?
Caribou Biosciences, Inc. (CRBU)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is CRBU's market cap?
Caribou Biosciences, Inc. (CRBU) has a market capitalization of $177.73M as of 2026-06-30.
What is CRBU's EPS (earnings per share)?
Caribou Biosciences, Inc. (CRBU)'s trailing twelve month EPS is $-1.02 as of 2026-06-30.
What is CRBU's ROE (return on equity)?
Caribou Biosciences, Inc. (CRBU)'s trailing twelve month Return on Equity (ROE) is -78.27% as of 2026-06-30.
What is CRBU's ROA (return on assets)?
Caribou Biosciences, Inc. (CRBU)'s trailing twelve month Return on Assets (ROA) is -56.87% as of 2026-06-30.
What is CRBU's ROIC (return on invested capital)?
Caribou Biosciences, Inc. (CRBU)'s trailing twelve month Return on Invested Capital (ROIC) is -102.71% as of 2026-06-30.
What is CRBU's EV/EBITDA?
Caribou Biosciences, Inc. (CRBU)'s trailing twelve month EV/EBITDA is -1.42x as of 2026-06-30.